Combined Tyrosine Kinase Inhibitors and Chemotherapy Based on Minimal Residual Disease in Children With Ph+ Acute Lymphoblastic Leukemia: A Phase 2 Single-Arm Trial, JCCG ALL-Ph13.

Key Points

• To evaluate the efficacy of combining tyrosine kinase inhibitors with chemotherapy in treating children with Ph+ acute lymphoblastic leukemia.
• Conducted a phase 2 single-arm trial
• Focused on children with Ph+ ALL
• Reduced intensity of hematopoietic stem cell transplantation (HSCT)
• Evaluated outcomes based on minimal residual disease
• Achieved comparable outcomes to previous studies
• Significant reduction in HSCT
• Indicated a need for optimizing TKI administration duration for better long-term event-free survival (EFS)